CAR-T Therapy Market: Global Industry Analysis 2015 to 2020 and Opportunity Assessment 2021 to 2027

  • Report ID: BMRC 1549 | Number of pages: 196 | Published Date: May 2021

    Published | Category: Healthcare | Delivery Timeline: 48 hrs

COVID-19
To know the impact of COVID-19 On CAR-T Therapy Market: Global Industry Analysis 2015 to 2020 and Opportunity Assessment 2021 to 2027 Market

Request Now
Market Size Forecast Scenarios (Optimistic, Baseline and Pessimistic) 2021-2027

Global CAR-T Therapy Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027- Rising occurrence of cancer, collaboration of biotech and pharma companies, increasing funding by government, development of latest and effective therapies to cure diseases are anticipated to drive the growth of Global CAR-T Therapy Market.

Global CAR-T Therapy Market is valued at USD 708.5 Million in 2020 and expected to reach USD 4791.1 Million by 2027 with a CAGR of 31.4% over the forecast period.

Scope of Global CAR-T Therapy Market Report:

Chimeric antigen receptor-T (CAR-T) cell therapy is an extremely encouraging therapy for cancer patients. CAR-T is a kind of immunotherapy where doctors collect immune cells from a patient, change cells in a research center and give cells the ability to easily identify and destroy cancer cells and mix it back into the patient. This arising therapy is possibly the greatest forward leap since the introduction of chemotherapy. The implanted cells get increased and stay in the body as living drugs. CAR-T cells are genetically designed cell receptors that are attached to the T-cells of the cancer patients and mixed through the circulation system that initiates the immune system to destroy cancer causing cells in the body. Also, CAR T-cell therapy is confirmed for patients with decline or inflexible acute lymphoblastic leukemia up to age 25. There are additionally numerous clinical trials of CAR T-cell therapy for different sorts of blood cancer and strong tumors.

COVID-19 pandemic has made huge interruption to the CAR-T therapy industry. Currently, the COVID-19 pandemic is influencing the consistency of essential routine medical care services and systems, including chimeric antigen receptor T-cell (CAR-T) therapy, a daily existence saving alternative for patients with relapsed/refractory hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. And, due to various restrictions during Covid-19 many existing trials and read outs have been delayed despite and new trials completely suspended. Thus, Covid-19 situation has shown a decline impact on the growth of Global CAR-T Therapy Market.

Global CAR-T therapy market is segmented on the basis of targeted antigen, application, end-user and region & country level. Based upon targeted antigen, CAR-T therapies market is classified into CD 19,CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso and EGFRvlll. Based upon application, the market is divided into acute lymphoblastic leukemia, diffuse large b-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma and others. Based upon end-user, CAR-T therapies market is classified into hospitals and cancer treatment centers.

Global CAR-T Therapy Market Segmentation:

By Targeted Antigen:

  • CD 19
  • CD 20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • HER2
  • Meso
  • EGFRvlll

By Application:

  • Acute Lymphoblastic Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Others

By End-User:

  • Hospitals
  • Cancer Treatment Centers

The regions covered in this Global CAR-T Therapy Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of global CAR-T therapies is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.

Key Players for Global CAR-T Therapy Market Report:

Some major key players for Global CAR-T Therapy Market report cover prominent players are Pfizer Inc., Novartis International AG, Noile-Immune Biotech Inc., Merck KGaA, Gilead Sciences Inc., Gracell Biotechnology Ltd, Aeon Therapeutics, Celegne, Celyad, Sangamo Therapeutics Inc., Cellectis, Johnson & Johnson, Amgen Inc., Celyad Oncology, Nanjing Legend Biotechnology Co. Ltd., Intellia Therapeutics, Celgene Corp. (acquired by Bristol-Myers Squibb), Caribou Biosciences Inc., Bluebird Bio Inc. Bellicum Pharmaceuticals Inc. and others.

CAR-T Therapy

News: Gracell Biotechnologies Announced Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL

March 31st, 2021; Gracell Biotechnologies Inc. had announced that first enrolled patient in their vital Phase 1/2 clinical investigation of GC007g, an allogeneic donor-derived against CD19 chimeric antigen receptor (CAR) - T cell treatment for the treatment of B-cell acute lymphoblastic leukemia (B-ALL). B-ALL, a main type of acute lymphoblastic leukemia (ALL), is one of the most common forms of cancer in children between the ages of two and five and adults over the age of 50. GC007g is an allogeneic HLA (human leukocyte antigen) - coordinated with benefactor derived CAR-T treatment.

Rising Prevalence of Cancer, Collaboration of Biotech and Pharma Companies, Increasing Funding by Government, Development of Latest and Effective Therapies to Cure Diseases are Driving the Market Growth

The major factor driving the growth of global CAR-T therapy market is increasing prevalence of cancer. As per the World Health Organization (WHO), cancer is second major causes for mortality around the world, representing an expected 10 million deaths every year. In 2018, 18.1 million individuals around the globe had cancer, and 9.6 million died from the diseases. In addition, growing number of partnerships between biotech and pharma companies are also fostering growth of the global CAR-T therapy market. As per a news published, in February 2018, Gilead Sciences Inc. joined forces with Sangamo Therapeutics Inc. for its gene-editing innovation to produce cancer treatment and it is assessed that the arrangement was worth USD 3 billion. Furthermore, rising development of latest and effective therapies to cure diseases is also supplementing the GLOBAL CAR-T therapy market. According to a news published on July 24th, 2020; FDA approved the third chimeric antigen receptor (CAR) T-cell therapy, this time giving a green light for Kite Pharma's brexucabtagene autoleucel, the principal cell-based gene treatment to treat relapsed or headstrong mantle cell lymphoma (MCL).

However, high costs associated with the CAR-T therapy and difficulties associated with the CAR-T cell process may hamper the market growth. In spite of that, implementation of actions with highly developed technologies and innovative treatment procedures can offer more opportunities for the further growth of the market.

North America is Expected to Dominate the Global CAR-T Therapy Market

North America is expected to dominate the global CAR-T therapy market owing to the rising number of cancer patients, presence of key players and landmark approvals of CAR T-Cell therapies by the U.S. FDA in this region. According to National Cancer Institute, in 2020, an expected 1,806,590 new cases of cancer was analyzed in the United States and 606,520 individuals expired from the diseases. For example, in November 2019, Precision BioSciences, Inc., a biotechnology organization produced a new generation allogeneic CAR-T treatment and is leading an ongoing trial of this treatment by making its most prominently the-shelf allogeneic CAR-T treatment competitor known as PBCAR0191. In U.S., the FDA approved a CAR-T cell treatment, supporting Kymriah in August 2017 and Yescarta in October 2017. Also,  Novartis created Kymriah, a CAR-T treatment used to treat intense lymphoblastic leukemia. Kite Pharma created Yescarta, a CAR-T treatment to treat adult patients with particular sorts of enormous B-cell lymphoma .

Europe is projected to capture the significant revenue share in the global CAR-T therapy market due to growing research and development in the cancer therapies by governments in this region. For example; According to a news published in April 2018, both Kymriah and Yescarta secured agreement in Europe from the EMA. Kymriah is for the treatment of pediatric patients and youthful grown-ups with unmanageable or backslide (R/R) B cell antecedent acute lymphoblastic leukemia (ALL), however Yescarta is used for the therapy of grown-up patients with R/R enormous B cell lymphoma.

Asia Pacific is expected to witness a fastest growth in the global CAR-T therapy market due to the increasing count of cancer patients and growing number of collaboration between government and private organizations in the region. For example; ongoing epidemiological investigations done at the National Cancer Registry program in India reported that disease trouble in the nation is 2.5 to 3 million and around 700,000 - 900,000 number of new cases analyzed per year.  Additionally, collaborations among different organizations and makers help in expanding the CAR-T therapies market in the future. For instance, EdiGene and Immunochina announced their partnership on R&D to create allogeneic CAR-T treatment for cancer in 2020. This partnership is further expected to create genome altering innovations to fast-track the drug invention and develop novel therapeutics for an expansive scope of illnesses.

Report Analysis Details
Historical data 2015 - 2020
Forecast Period 2021 - 2027
Market Size in 2020: USD 708.5 Million
Base year considered 2020
Forecast Period CAGR %:

31.40 %

Market Size Expected in 2027: USD 4791.1 Million
Tables, Charts & Figures: 175
Pages 200
Key Players/Companies Pfizer Inc., Novartis International AG, Noile-Immune Biotech Inc., Merck KGaA, Gilead Sciences Inc., Gracell Biotechnology Ltd, Aeon Therapeutics, Celegne, Celyad, Sangamo Therapeutics Inc., Cellectis, Johnson & Johnson, Amgen Inc., Celyad Oncology, Nanjing Legend Biotechnology Co. Ltd., Intellia Therapeutics, Celgene Corp. (acquired by Bristol-Myers Squibb), Caribou Biosciences Inc., Bluebird Bio Inc. Bellicum Pharmaceuticals Inc. and others
Segments Covered By Targeted Antigen, By Application, By End-User
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for Global CAR-T Therapy Market Report:

  • Global CAR-T Therapy Market report covers in-depth historical and forecast analysis.
  • Global CAR-T Therapy Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
  • Global CAR-T Therapy Market report helps to identify opportunities in marketplace.
  • Global CAR-T Therapy Market report covers extensive analysis of emerging trends and competitive landscape.

CAR-T Therapy Market By Regional & Country Level:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

Latin America

  • Brazil
  • Mexico

Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

 


Frequently Asked Questions (FAQ) :
Global CAR-T Therapy Market is valued at USD 708.5 Million in 2020 and expected to reach USD 4791.1 Million by 2027 with a CAGR of 31.4% over the forecast period.
North America is expected to dominate the global CAR-T therapy market owing to the rising number of cancer patients, presence of key players and landmark approvals of CAR T-Cell therapies by the U.S. FDA in this region
Rising occurrence of cancer, collaboration of biotech and pharma companies, increasing funding by government, development of latest and effective therapies to cure diseases are anticipated to drive the growth of Global CAR-T Therapy Market
Pfizer Inc., Novartis International AG, Noile-Immune Biotech Inc., Merck KGaA, Gilead Sciences Inc., Gracell Biotechnology Ltd, Aeon Therapeutics, Celegne, Celyad, Sangamo Therapeutics Inc., Cellectis, Johnson & Johnson, Amgen Inc., Celyad Oncology, Nanjing Legend Biotechnology Co. Ltd., Intellia Therapeutics, Celgene Corp. (acquired by Bristol-Myers Squibb), Caribou Biosciences Inc., Bluebird Bio Inc. Bellicum Pharmaceuticals Inc. and others



Interested in this report?

CAR-T Therapy Market Growth Analysis By Targeted Antigen, By Application, By End-User Forecast to 2027 and Analysis 2019-2025

report cover

CAR-T Therapy Market: Global Industry Analysis 2015 to 2020 and Opportunity Assessment 2021 to 2027

Note: For delivery of sample pages you must have a Domain Specific Email ID, normally your business email address complies. Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSNetc. are not accepted.

    Pricing


Looking for Regional Reports?